The Secondary (Hypogonadotropic) Hypogonadism drugs in development market research report provides comprehensive information on the therapeutics under development for Secondary (Hypogonadotropic) Hypogonadism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Secondary (Hypogonadotropic) Hypogonadism. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Secondary (Hypogonadotropic) Hypogonadism and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Secondary (Hypogonadotropic) Hypogonadism by seven companies/universities/institutes. The top development phase for Secondary (Hypogonadotropic) Hypogonadism is phase ii with three drugs in that stage. The Secondary (Hypogonadotropic) Hypogonadism pipeline has six drugs in development by companies and one by universities/ institutes. Some of the companies in the Secondary (Hypogonadotropic) Hypogonadism pipeline products market are: Massachusetts General Hospital, Shenzhen Salubris Pharmaceuticals and AbbVie.
The key targets in the Secondary (Hypogonadotropic) Hypogonadism pipeline products market include Androgen Receptor, Follicle Stimulating Hormone Receptor, and Estrogen Receptor.
The key mechanisms of action in the Secondary (Hypogonadotropic) Hypogonadism pipeline product include Follicle Stimulating Hormone Receptor Agonist with two drugs in Phase II. The Secondary (Hypogonadotropic) Hypogonadism pipeline products include five routes of administration with the top ROA being Oral and four key molecule types in the Secondary (Hypogonadotropic) Hypogonadism pipeline products market including Small Molecule, and Synthetic Peptide.
Secondary (Hypogonadotropic) Hypogonadism overview
Hypogonadotropic hypogonadism (HH) is a form of hypogonadism caused by a problem with the pituitary gland or hypothalamus. HH is caused by a lack of hormones that normally stimulate the ovaries or testes, like gonadotropin-releasing hormone (GnRH), follicle stimulating hormone (FSH), and luteinizing hormone (LH). Symptoms include a lack of development at puberty, enlargement of the testes and penis, deepening of the voice, and facial hair. Treatment includes testosterone, estrogen, and progesterone.
For a complete picture of Secondary (Hypogonadotropic) Hypogonadism’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
